Main image

Fewer Injection Site Reactions In Patients Using AVONEX Versus Sub-cutaneous Interferon And Glatiramer Acetate For The Treatment Of Multiple Sclerosis

13th September
2009
written by Multiple Sclerosis News From Medical News Today

Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon® (interferon beta-1b), Copaxone® (glatiramer Acetate) or Rebif ®(interferon beta-1a).

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • email
  • Print
  • StumbleUpon
  • YahooMyWeb
Multiple Sclerosis
Comments are closed.